Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Parkinson's Disease

  Free Subscription


Articles published in Ann Neurol

Retrieve available abstracts of 99 articles:
HTML format



Single Articles


    October 2024
  1. CHERIF S, Tempier N, Yeche M, Temiz G, et al
    Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Parkinson's Disease Patients: A Randomized Controlled Study.
    Ann Neurol. 2024 Oct 30. doi: 10.1002/ana.27099.
    PubMed     Abstract available


    September 2024
  2. BRUMBERG J, Blazhenets G, Buhler S, Fostitsch J, et al
    Cerebral Glucose Metabolism Is a Valuable Predictor of Survival in Patients with Lewy Body Diseases.
    Ann Neurol. 2024;96:539-550.
    PubMed     Abstract available


  3. CAMERUCCI E, Mullan AF, Turcano P, Stang CD, et al
    A Population-Based Approach to the Argument on Brain-First and Body-First Pathogenesis of Lewy Body Disease.
    Ann Neurol. 2024;96:551-559.
    PubMed     Abstract available


    August 2024
  4. PUIG-DAVI A, Martinez-Horta S, Perez-Carasol L, Horta-Barba A, et al
    Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4-Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers.
    Ann Neurol. 2024 Aug 5. doi: 10.1002/ana.27035.
    PubMed     Abstract available


    May 2024
  5. ARENA G, Landoulsi Z, Grossmann D, Payne T, et al
    Polygenic Risk Scores Validated in Patient-Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease.
    Ann Neurol. 2024 May 20. doi: 10.1002/ana.26949.
    PubMed     Abstract available


  6. SAARINEN EK, Kuusimaki T, Lindholm K, Niemi K, et al
    Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease.
    Ann Neurol. 2024 May 20. doi: 10.1002/ana.26957.
    PubMed     Abstract available


  7. ZAMPOGNA A, Suppa A, Bove F, Cavallieri F, et al
    Disentangling Bradykinesia and Rigidity in Parkinson Disease: Evidence from Short- and Long-Term Subthalamic Nucleus Deep Brain Stimulation.
    Ann Neurol. 2024 May 9. doi: 10.1002/ana.26961.
    PubMed     Abstract available


  8. PRASUHN J, Schiefen T, Guber T, Henkel J, et al
    Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo.
    Ann Neurol. 2024;95:849-857.
    PubMed     Abstract available


    April 2024
  9. GONZALEZ-LATAPI P, Bustos B, Dong S, Lubbe S, et al
    Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease.
    Ann Neurol. 2024 Apr 2. doi: 10.1002/ana.26923.
    PubMed     Abstract available


  10. POST E, Hall DA, Bloem BR
    Reply to "An Apple a Day Will Not Keep the (Parkinson's Disease) Doctor at Bay!".
    Ann Neurol. 2024 Apr 1. doi: 10.1002/ana.26937.
    PubMed    


  11. KHANI M, Cerquera-Cleves C, Kekenadze M, Wild Crea P, et al
    Towards a Global View of Parkinson's Disease Genetics.
    Ann Neurol. 2024 Apr 1. doi: 10.1002/ana.26905.
    PubMed     Abstract available


  12. SAKOWSKI SA, Koubek EJ, Chen KS, Goutman SA, et al
    Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions.
    Ann Neurol. 2024;95:635-652.
    PubMed     Abstract available


    March 2024
  13. BOOGERS A, Fasano A, Lang A
    An Apple a Day Will Not Keep the (Parkinson Disease) Doctor at Bay!
    Ann Neurol. 2024 Mar 30. doi: 10.1002/ana.26936.
    PubMed    


  14. KLUGE A, Borsche M, Streubel-Gallasch L, Gul T, et al
    alpha-Synuclein Pathology in PRKN-Linked Parkinson's Disease: New Insights from a Blood-Based Seed Amplification Assay.
    Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26917.
    PubMed     Abstract available


  15. DEL BENE VA, Martin RC, Brinkerhoff SA, Olson JW, et al
    Differential Cognitive Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease.
    Ann Neurol. 2024 Mar 19. doi: 10.1002/ana.26903.
    PubMed     Abstract available


  16. ARNALDI D, Mattioli P, Raffa S, Pardini M, et al
    Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26902.
    PubMed     Abstract available


    December 2023
  17. WIESMAN AI, da Silva Castanheira J, Fon EA, Baillet S, et al
    Alterations of cortical structure and neurophysiology in Parkinson's disease are aligned with neurochemical systems.
    Ann Neurol. 2023 Dec 26. doi: 10.1002/ana.26871.
    PubMed     Abstract available


  18. REYNOSO A, Torricelli R, Jacobs BM, Shi J, et al
    Gene-environment interactions for Parkinson's disease.
    Ann Neurol. 2023 Dec 19. doi: 10.1002/ana.26852.
    PubMed     Abstract available


    November 2023
  19. ZHOU L, Li SX, Chau SW, Huang B, et al
    Altered impulsivity across drug-naive parkinsonism, isolated REM sleep behavior disorder, and their high-risk relatives.
    Ann Neurol. 2023 Nov 23. doi: 10.1002/ana.26836.
    PubMed     Abstract available


  20. CHUN MY, Chung SJ, Kim SH, Park CW, et al
    Hippocampal Perfusion Affects Motor and Cognitive Functions in Parkinson's Disease: An Early-Phase (18) F-FP-CIT PET Study.
    Ann Neurol. 2023 Nov 14. doi: 10.1002/ana.26827.
    PubMed     Abstract available


    August 2023
  21. MOHAMMADZADEH N, Tung GA, Prakash P, Alhusaini S, et al
    Parkinsonism: A Rare Complication of Cerebral Toxoplasmosis.
    Ann Neurol. 2023 Aug 30. doi: 10.1002/ana.26777.
    PubMed    


  22. KANG X, Ploner A, Roelstraete B, Ludvigsson JF, et al
    Risk of Parkinson's disease in celiac disease: A Swedish population-based study.
    Ann Neurol. 2023 Aug 26. doi: 10.1002/ana.26780.
    PubMed     Abstract available


    June 2023
  23. HE P, Shi L, Li Y, Duan Q, et al
    The Association of the Glymphatic Function with Parkinson's Disease Symptoms: Neuroimaging Evidence from Longitudinal and Cross-sectional Studies.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26729.
    PubMed     Abstract available


  24. NIETHAMMER M, Tang CC, Jamora RDG, Vo A, et al
    A network imaging biomarker of X-linked dystonia-parkinsonism.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26732.
    PubMed     Abstract available


  25. PALACIOS N, Wilkinson J, Bjornevik K, Schwarzschild MA, et al
    Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes.
    Ann Neurol. 2023 Jun 14. doi: 10.1002/ana.26719.
    PubMed     Abstract available


    May 2023
  26. HACKER ML, Rajamani N, Neudorfer C, Hollunder B, et al
    Connectivity Profile for Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.
    Ann Neurol. 2023 May 13. doi: 10.1002/ana.26674.
    PubMed     Abstract available


  27. WILKINS KB, Kehnemouyi YM, Petrucci MN, Anderson RW, et al
    Bradykinesia and Its Progression Are Related to Interhemispheric Beta Coherence.
    Ann Neurol. 2023;93:1029-1039.
    PubMed     Abstract available


    April 2023
  28. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    PubMed     Abstract available


    March 2023
  29. LIU B, Svenningsson P, Ludvigsson JF, Lundholm C, et al
    beta2-adrenoreceptor agonists, montelukast, and Parkinson's disease risk.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26638.
    PubMed     Abstract available


  30. LANORE A, Casse F, Tesson C, Courtin T, et al
    Differences in survival across monogenic forms of Parkinson's disease.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26636.
    PubMed     Abstract available


  31. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    PubMed    


  32. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    PubMed    


    February 2023
  33. JACOB MA, Cai M, Bergkamp M, Darweesh SKL, et al
    Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism.
    Ann Neurol. 2023 Feb 10. doi: 10.1002/ana.26615.
    PubMed     Abstract available


  34. MIYAMOTO K, Saiki S, Matsumoto H, Suzuki A, et al
    Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD.
    Ann Neurol. 2023;93:303-316.
    PubMed     Abstract available


    January 2023
  35. BLOEM BR, Post E, Hall D
    An Apple a day to keep the Parkinson's disease doctor away?
    Ann Neurol. 2023 Jan 27. doi: 10.1002/ana.26612.
    PubMed     Abstract available


  36. BILLINGSLEY KJ, Ding J, Alvarez Jerez P, Illarionova A, et al
    Genome-wide analysis of Structural Variants in Parkinson's Disease.
    Ann Neurol. 2023 Jan 25. doi: 10.1002/ana.26608.
    PubMed     Abstract available


  37. HANSSEN H, Diesta CCE, Heldmann M, Dy J, et al
    Basal Ganglia Atrophy as a Marker for Prodromal X-linked Dystonia-Parkinsonism.
    Ann Neurol. 2023 Jan 16. doi: 10.1002/ana.26606.
    PubMed     Abstract available


  38. RAY NJ, Kanel P, Bohnen NI
    Atrophy of the cholinergic basal forebrain can detect presynaptic cholinergic loss in Parkinson's disease.
    Ann Neurol. 2023 Jan 4. doi: 10.1002/ana.26596.
    PubMed     Abstract available


    November 2022
  39. DE BARTOLO MI, Vivacqua G, Belvisi D, Mancinelli R, et al
    A combined panel of salivary biomarkers in de novo Parkinson's Disease.
    Ann Neurol. 2022 Nov 16. doi: 10.1002/ana.26550.
    PubMed     Abstract available


  40. MARTIN WRW, Younce JR, Campbell MC, Racette BA, et al
    Neocortical Lewy body pathology parallels Parkinson's dementia, but not always.
    Ann Neurol. 2022 Nov 4. doi: 10.1002/ana.26542.
    PubMed     Abstract available


  41. GARRIDO A, Perez-Sisques L, Simonet C, Campoy-Campos G, et al
    Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.
    Ann Neurol. 2022;92:888-894.
    PubMed     Abstract available


    October 2022
  42. SCHIRINZI T, Maftei D, Passali FM, Grillo P, et al
    Olfactory neuron Prokineticin-2 as a potential target in Parkinson's disease.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26526.
    PubMed     Abstract available


  43. RASCHELLA F, Scafa S, Puiatti A, Martin Moraud E, et al
    Actigraphy enables home screening of REM behavior disorder in Parkinson disease.
    Ann Neurol. 2022 Oct 4. doi: 10.1002/ana.26517.
    PubMed     Abstract available


    September 2022
  44. FUNG WK, Cohn M, Lang AE, Fasano A, et al
    Precision vs. Personalized DBS for GBA-related Parkinson disease.
    Ann Neurol. 2022 Sep 2. doi: 10.1002/ana.26499.
    PubMed    


    August 2022
  45. AL-MUBARAK B, Ahmed Nour M, Schumacher-Schuh A, Bandres-Ciga S, et al
    Globalizing research towards diverse representation in Alzheimer's and Parkinson's disease.
    Ann Neurol. 2022 Aug 24. doi: 10.1002/ana.26483.
    PubMed    


  46. MARIN-LAHOZ J, Martinez-Horta S, Pagonabarraga J, Horta-Barba A, et al
    Predicting Impulse Control Disorders in Parkinson's disease through incentive biomarkers.
    Ann Neurol. 2022 Aug 19. doi: 10.1002/ana.26486.
    PubMed     Abstract available


  47. PERINAN MT, Brolin K, Bandres-Ciga S, Blauwendraat C, et al
    Effect modification between genes and environment, and Parkinson's disease risk.
    Ann Neurol. 2022 Aug 1. doi: 10.1002/ana.26467.
    PubMed     Abstract available


    July 2022
  48. KENT DM, Leung LY, Puttock EJ, Wang AY, et al
    Development of Parkinson's disease and its relationship with incidentally-discovered white matter disease and covert brain infarction in a real-world cohort.
    Ann Neurol. 2022 Jul 22. doi: 10.1002/ana.26458.
    PubMed     Abstract available


  49. BOLLIRI C, Fontana A, Cereda E, Barichella M, et al
    Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease.
    Ann Neurol. 2022 Jul 19. doi: 10.1002/ana.26454.
    PubMed     Abstract available


    June 2022
  50. PRANGE S, Lin Z, Nourredine M, Danaila T, et al
    Limbic stimulation drives mania in STN-DBS in Parkinson disease: a prospective study.
    Ann Neurol. 2022 Jun 15. doi: 10.1002/ana.26434.
    PubMed     Abstract available


  51. PAL G, Mangone G, Ouyang B, Ehrlich D, et al
    Reply to: Cognitive effects of deep brain stimulation in GBA-related Parkinson's disease.
    Ann Neurol. 2022 Jun 10. doi: 10.1002/ana.26433.
    PubMed    


  52. WEILL C, Gallant A, Lintsky E, Dienstag A, et al
    Cognitive effects of deep brain stimulation in GBA-related Parkinson's disease.
    Ann Neurol. 2022 Jun 10. doi: 10.1002/ana.26432.
    PubMed    


    May 2022
  53. LIU H, Dehestani M, Blauwendraat C, Makarious MB, et al
    Polygenic resilience modulates the penetrance of Parkinson's disease genetic risk factors.
    Ann Neurol. 2022 May 22. doi: 10.1002/ana.26416.
    PubMed     Abstract available


  54. HUANG Y, Liu Z, Li N, Tian C, et al
    Parkinson's disease derived exosomes aggravate neuropathology in SNCA*A53T mice.
    Ann Neurol. 2022 May 21. doi: 10.1002/ana.26421.
    PubMed     Abstract available


  55. SHEN J, Amari N, Zack R, Skrinak RT, et al
    Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson's Disease.
    Ann Neurol. 2022 May 20. doi: 10.1002/ana.26410.
    PubMed     Abstract available


    April 2022
  56. CRAMER SW, Do TH, Palzer EF, Naik A, et al
    Persistent racial disparities in deep brain stimulation for Parkinson's disease.
    Ann Neurol. 2022 Apr 19. doi: 10.1002/ana.26378.
    PubMed     Abstract available


  57. FURUKAWA K, Shima A, Kambe D, Nishida A, et al
    Motor progression and nigrostriatal neurodegeneration in Parkinson's disease.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26373.
    PubMed     Abstract available


    February 2022
  58. MONTENEGRO P, Pueyo M, Lorenzo JN, Villar MD, et al
    A secretory vesicle failure in Parkinson's disease occurs in human platelets.
    Ann Neurol. 2022 Feb 28. doi: 10.1002/ana.26335.
    PubMed     Abstract available


    January 2022
  59. TOSSERAMS A, Weerdesteyn V, Bal T, Bloem BR, et al
    Cortical correlates of gait compensation strategies in Parkinson's disease.
    Ann Neurol. 2022 Jan 24. doi: 10.1002/ana.26306.
    PubMed     Abstract available


  60. PAL G, Mangone G, Hill EJ, Ouyang B, et al
    Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26302.
    PubMed     Abstract available


    December 2021
  61. JOHANSSON ME, Cameron IGM, van der Kolk NM, De Vries NM, et al
    Aerobic exercise alters brain function and structure in Parkinson's disease a randomized controlled trial.
    Ann Neurol. 2021 Dec 24. doi: 10.1002/ana.26291.
    PubMed     Abstract available


    November 2021
  62. VILLANUEVA EB, Tresse E, Liu Y, Duarte JN, et al
    Neuronal TNFalpha, Not alpha-Syn, Underlies PDD-Like Disease Progression in IFNbeta-KO Mice.
    Ann Neurol. 2021;90:789-807.
    PubMed     Abstract available


    August 2021
  63. ZHANG C, Lai Y, Li J, He N, et al
    Subthalamic and pallidal stimulations in patients with Parkinson's disease: common and dissociable connections.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26199.
    PubMed     Abstract available


  64. VERGER A, Grimaldi S, Ribeiro MJ, Frismand S, et al
    SPECT/PET molecular imaging for parkinsonism: a fast-developing field.
    Ann Neurol. 2021 Aug 2. doi: 10.1002/ana.26187.
    PubMed     Abstract available


    July 2021
  65. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    PubMed    


  66. WEISS D, Volkmann J, Fasano A, Kuhn A, et al
    Neurology Grand Rounds: Changing gears - DBS for dopaminergic desensitization in Parkinson's disease?
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26164.
    PubMed     Abstract available


  67. LOESCH DP, Horimoto ARVR, Heilbron K, Sarihan EI, et al
    Characterizing the Genetic Architecture of Parkinson's Disease in Latinos.
    Ann Neurol. 2021 Jul 6. doi: 10.1002/ana.26153.
    PubMed     Abstract available


    June 2021
  68. DARVISH H, Azcona LJ, Taghavi S, Firouzabadi SG, et al
    ANXA1 with anti-inflammatory properties might contribute to parkinsonism.
    Ann Neurol. 2021 Jun 28. doi: 10.1002/ana.26148.
    PubMed     Abstract available


  69. SINGER W, Schmeichel AM, Shahnawaz M, Schmelzer JD, et al
    Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
    Ann Neurol. 2021;89:1212-1220.
    PubMed     Abstract available


    May 2021
  70. HEINZEL S, Aho VTE, Suenkel U, von Thaler AK, et al
    Gut microbiome signatures of risk and prodromal markers of Parkinson's disease.
    Ann Neurol. 2021 May 22. doi: 10.1002/ana.26128.
    PubMed     Abstract available


  71. ALBIN RL, Muller MLTM, Bohnen NI, Spino C, et al
    alpha4beta2(*) Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.
    Ann Neurol. 2021 May 11. doi: 10.1002/ana.26102.
    PubMed     Abstract available


  72. LAI D, Alipanahi B, Fontanillas P, Schwantes-An TH, et al
    Genome-wide association studies of LRRK2 modifiers of Parkinson's disease.
    Ann Neurol. 2021 May 2. doi: 10.1002/ana.26094.
    PubMed     Abstract available


  73. KLEIN C, Konig IR
    Exploring uncharted territory: genetically determined sex differences in Parkinson's disease.
    Ann Neurol. 2021 May 2. doi: 10.1002/ana.26091.
    PubMed    


    April 2021
  74. BLAUWENDRAAT C, Iwaki H, Makarious MB, Bandres-Ciga S, et al
    Investigation of Autosomal Genetic Sex Differences in Parkinson's disease.
    Ann Neurol. 2021 Apr 26. doi: 10.1002/ana.26090.
    PubMed     Abstract available


  75. RUSZ J, Hlavnicka J, Novotny M, Tykalova T, et al
    Speech biomarkers in rapid eye movement sleep behaviour disorder and Parkinson's disease.
    Ann Neurol. 2021 Apr 15. doi: 10.1002/ana.26085.
    PubMed     Abstract available


    March 2021
  76. ROSEBRAUGH M, Voight EA, Moussa EM, Jameel F, et al
    Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson's disease.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26073.
    PubMed     Abstract available


  77. ELIAS GJB, Boutet A, Joel SE, Germann J, et al
    Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy.
    Ann Neurol. 2021;89:426-443.
    PubMed     Abstract available


    February 2021
  78. LE GUEN Y, Napolioni V, Belloy ME, Yu E, et al
    Common X-chromosome variants are associated with Parkinson's disease risk.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26051.
    PubMed     Abstract available


  79. JENSEN MP, Jacobs BM, Dobson R, Bandres-Ciga S, et al
    Lower lymphocyte count is associated with increased risk of Parkinson's disease.
    Ann Neurol. 2021 Feb 2. doi: 10.1002/ana.26034.
    PubMed     Abstract available


  80. RAHAYEL S, Postuma RB, Montplaisir J, Misic B, et al
    A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies.
    Ann Neurol. 2021;89:341-357.
    PubMed     Abstract available


  81. STANG CD, Mullan AF, Hajeb M, Camerucci E, et al
    Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt Alpha-Synucleinopathies.
    Ann Neurol. 2021;89:293-303.
    PubMed     Abstract available


    January 2021
  82. ANDERSEN MS, Bandres-Ciga S, Reynolds RH, Hardy J, et al
    Heritability enrichment implicates microglia in Parkinson's disease pathogenesis.
    Ann Neurol. 2021 Jan 27. doi: 10.1002/ana.26032.
    PubMed     Abstract available


    December 2020
  83. YAU WY, Sullivan R, Rocca C, Cali E, et al
    NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease in Patients of European Descent.
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26003.
    PubMed    


  84. SHI CH, Fan Y, Xu YM
    Reply to "NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease".
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26005.
    PubMed    


  85. CAVALLIERI F, Fraix V, Bove F, Mulas D, et al
    Predictors of long-term outcome of subthalamic stimulation in Parkinson disease.
    Ann Neurol. 2020 Dec 21. doi: 10.1002/ana.25994.
    PubMed     Abstract available


  86. TAN AH, Chong CW, Lim SY, Yap IKS, et al
    Gut microbial ecosystem in Parkinson's disease: New clinico-biological insights from multi-omics.
    Ann Neurol. 2020 Dec 3. doi: 10.1002/ana.25982.
    PubMed     Abstract available


  87. SHEN L, Jiang C, Hubbard CS, Ren J, et al
    Subthalamic Nucleus Deep Brain Stimulation Modulates 2 Distinct Neurocircuits.
    Ann Neurol. 2020;88:1178-1193.
    PubMed     Abstract available


    November 2020
  88. LEE JY, Ahn J, Shin J, Jeon B, et al
    Parafovea change and dopamine loss in the retina with Parkinson's disease.
    Ann Neurol. 2020 Nov 24. doi: 10.1002/ana.25972.
    PubMed    


    October 2020
  89. KIM CY, Wirth T, Hubsch C, Nemeth AH, et al
    Reply to "PPP2R5D genetic mutations and early-onset parkinsonism".
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25945.
    PubMed    


  90. MURUETA-GOYENA A, Del Pino R, Galdos M, Arana B, et al
    Retinal thickness predicts the risk of cognitive decline in Parkinson's disease.
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25944.
    PubMed     Abstract available


  91. DULOVIC-MAHLOW M, Konig IR, Trinh J, Diaw SH, et al
    Discordant monozygotic Parkinson disease twins: Role of mitochondrial integrity.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25942.
    PubMed     Abstract available


  92. WALKER IM, Riboldi GM, Drummond P, Saade-Lemus S, et al
    PPP2R5D genetic mutations and early-onset parkinsonism.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25943.
    PubMed    


  93. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    PubMed     Abstract available


  94. SHI CH, Fan Y, Yang J, Yuan YP, et al
    NOTCH2NLC Intermediate-length Repeat Expansions are Associated with Parkinson's Disease.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25925.
    PubMed     Abstract available


  95. LESAGE S, Lunati A, Houot M, Romdhan SB, et al
    Characterization of Recessive Parkinson Disease in a Large Multicenter Study.
    Ann Neurol. 2020;88:843-850.
    PubMed     Abstract available


    September 2020
  96. NUBER S, Nam AY, Rajsombath MM, Cirka H, et al
    A stearoyl-CoA desaturase inhibitor prevents multiple Parkinson's disease-phenotypes in alpha-synuclein mice.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25920.
    PubMed     Abstract available


  97. SINGER W, Schmeichel AM, Shahnawaz M, Schmelzer JD, et al
    Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Ann Neurol. 2020;88:503-512.
    PubMed     Abstract available


    June 2020
  98. IRMEN F, Horn A, Mosley P, Perry A, et al
    Left Prefrontal Connectivity Links Subthalamic Stimulation with Depressive Symptoms.
    Ann Neurol. 2020;87:962-975.
    PubMed     Abstract available


  99. MONZON-SANDOVAL J, Poggiolini I, Ilmer T, Wade-Martins R, et al
    Human-Specific Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons.
    Ann Neurol. 2020;87:853-868.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.